Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: Sequential analysis and predictive ability in dogs with lymphoma

Journal of Veterinary Internal Medicine

Volumn 10, Issue 6, 1996, Pages 354-359

  Bergman, Philip J ^a,b   Ogilvie, Gregory K ^a   Powers, Barbara E ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PADGEM PROTEIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHEMISTRY; DOG; DOG DISEASE; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPHOMA; MALE; METHODOLOGY; MORTALITY; NECROSIS; PATHOLOGY; PREDICTION AND FORECASTING; SURVIVAL RATE; TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; DOG DISEASES; DOGS; FEMALE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MALE; NECROSIS; P-SELECTIN; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE; TIME FACTORS;

EID: 0030278180     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.1996.tb02080.x     Document Type: Article

References (43)

1. Fojo AT. Multidrug resistance. Adv Intern Med 1991;36:195-218.
2. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987;316:1388-1396.
3. Carter RF, Harris CK, Withrow SJ, et al. Chemotherapy of canine lymphoma with histopathological correlation: Doxorubicin alone compared to COP as first treatment regimen. J Am Anim Hosp Assoc 1987;23:587-596.
4. Wolf DC, Horwitz SB. P-glycoprotein transports corticosterone and is photoaffinity-labeled by the steroid. Int J Cancer 1992; 52:141-146.
5. Price GS, Page RL, Fischer BM, et al. Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphoma. J Vet Intern Med 1991;5:259-262.
6. Chieli E, Santoni-Rugiu E, Cervelli F, et al. Differential modulation of P-glycoprotein expression by dexamethasone and 3-methycholanthrene in rat hepatocyte primary cultures. Carcinogenesis 1994;15:335-341.
7. Tsuji A, Terasaki T, Takabatake Y, et al. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci 1992;51:1427-1437.
8. Fojo AT, Ueda K, Slamon DJ, et al. Expression of an mdr gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84:265-269.
9. Drach D, Zhao S, Drach J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistance phenotype. Blood 1992;80:2729-2734.
10. van Kalken CK, Giaccone G, van der Valk P, et al. Multidrug resistance gene (p-glycoprotein) expression in the human fetus. Am J Pathol 1992; 141:1063-1072.
11. Mickisch GH, Pai LH, Siegsmund M. Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinoma and in MDR-transgenic mice. J Urol 1993; 149:174-178.
12. Huang C, Wu M. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 1992;84:262-264.
13. Chan HSL, Thorner PS, Haddad G, et al. Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990;8:689-704.
14. Chan HSL, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991;325:1608-1614.
15. Thiebaut F, Tsuruo T, Hamada H, et al. Immunohistochemical localization in normal tissues of different epitopes in a multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1988;37:389-394.
16. Grogan TN, Dalton WS, Rybski J, et al. Optimization of immunocytochemical P-glycoprotein assessment in multidrug resistant plasma cell myeloma using 3 antibodies. Lab Invest 1991;63: 815-824.
17. Ginn P. Immunohistochemical detection of p-glycoprotein in formalin-fixed, paraffin-embedded normal and neoplastic tissues using three monoclonal antibodies, JSB-1, C494, and C219. Vet Pathol 1994;31:624(abstr).
18. Moore AS, Leveille CR, Reimann KA, et al. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Invest 1995;13:475-479.
19. Chan HSL, Bradley G, Thorner P, et al. A sensitive method for immunocytochemical detection for P-glycoprotein in multidrug-resistant human ovarian carcinoma cell lines. Lab Invest 1988;59: 870-875.
20. Mattem J, Volm M. Prediction of drug resistance in human tumors using immunohistochemical techniques. Anticancer Res 1992;12:413-418.
21. Efferth T, Mattern J, Volm M. Immunohistochemical detection of P-glycoprotein, glutathione-s-transferase and DNA topoisomerase II in human tumors. Oncology 1992;49:368-375.
22. Owen LN. TNM classification of Tumours in Domestic Animals, 1st ed. Geneva, Switzerland: World Health Organization; 1980.
23. Anderson S, Anguier A, Hauck WN, et al. Statistical methods for comparative studies. New York, NY: Wiley; 1980:199-234.
24. Dixon WJ. Survival analysis. In: Dixon WJ, ed. BMDP Statistical. Berkeley, CA: University of California; 1981:555-594.
25. Page RL, Macy DW, Ogilvie GK, et al. Phase III evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphoma. Int J Hypertherm 1992;8:187-197.
26. Teicher BA. Lonidamine: In vitro/in vivo correlations. Eur J Cancer 1994;30A:1411-1413.
27. MacEwen EG, Hayes AA, Malus RE, et al. Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog: 147 cases (1978-1981). J Am Vet Med Assoc 1987; 190:564-568.
28. Greenlee PG, Filippa DA, Quimby FW, et al. Lymphomas in dogs: A morphologic, immunologic, and clinical study. Cancer 1990; 66:480-490.
29. Arrington KA, Legendre AM, Tabeling GS, et al. Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs. Am J Vet Res 1994;55:1587-1592.
30. Bergman PJ, MacEwen EG, Kurzman IG, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991-1993). J Vet Intern Med 1996; 10:76-81.
31. Fuqua SAW, Moretti-Rojas IM, Scneider SL, et al. P-glycoprotein expression in human breast cancer cells. Cancer Res 1992; 47:2103-2106.
32. Noonan KE, Beck C, Holzmayer TE, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87:7160-7164.
33. Miller TP, Grogan TM, Dalton WS, et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J Clin Oncol 1991;9:17-24.
34. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81: 116-124.
35. Grogan TM, Spier CM, Salmon SE, et al. P-glycoprotein expression in human plasma cell myeloma: An acquired trait related to prior chemotherapy. Blood 1993;81:490-495.
36. Epstein J, Xiao H, Oba BK. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 1989;74:913-917.
37. Rao VV, Anthony DC, Piwnica-Worms D. MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res 1994;54:1536-1541.
38. Ramu A, Spanier R, Rahaminoff H, et al. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukemia cells. Br J Cancer 1984;50:501-507.
39. Beck WT. Modulators of P-glycoprotein associated drug resistance. In: Ozols RF, ed. Molecular and Clinical Advances in Anticancer Drug Resistance. Norwell, MA: Kluwer; 1991:151-170.
40. Ozols RF, Cunnion RE, Klecker RW, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987;5:641-647.
41. Sakata K, Kwok TT, Gordon GR, et al. Resistance to verapamil sensitization of multidrug-resistant cells grown as multicellular spheroids. Int J Cancer 1994; 59:282-286.
42. Goldstein LJ. Clinical reversal of drug resistance. Curr Prob Cancer 1995; 19:65-124.
43. Bergman PJ, Ogilvie GK. Drug resistance and cancer therapy. Compend Contin Educ 1995; 17:549-560.